Search clinical trials for: INSULIN GLARGINE (U300)

Total 4031 results

Eli Lilly and Company

Completed

A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Taiwan, China, Korea, Republic of
Rabin Medical Center
Sanofi

Terminated

Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents

Diabetes Type 1

Israel
Sanofi

Completed

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Diabetes Mellitus, Insulin-Dependent

United States
University of Maryland, Baltimore

Completed

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

Diabetic Ketoacidosis

United States
Sanofi

Completed

Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. (DINAMO)

Diabetes Mellitus, Type 2

Brazil
Eli Lilly and Company

Completed

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (IOOV)

Diabetes Mellitus, Type 2

United States, Canada, India, Puerto Rico, Australia, Spain, Netherlands, Hungary, Brazil, Greece, Romania, Argentina
The Cleveland Clinic

Terminated

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management

Type 1 Diabetes | Type 2 Diabetes | Diabetic Ketoacidosis

United States
Amsterdam UMC, location VUmc

Completed

Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure

Type 2 Diabetes Mellitus | Congestive Heart Failure

Netherlands
Sanofi

Completed

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

United States, Chile, Czech Republic, Denmark, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Slovakia, Sweden
Northumbria University
Newcastle University

Completed

Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM

Type 1 Diabetes Mellitus

United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes (EUROMIX)

Diabetes Mellitus, Type 2 | Diabetes

Austria, Hungary, Slovenia, Germany, Czech Republic, Poland, Slovakia
Guillermo Umpierrez, MD
Medical University of South Carolina; Sanofi; Texas A&M University

Completed

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM) (Basal-Plus)

Hyperglycemia | Type 2 Diabetes

United States
HealthPartners Institute
Sanofi; International Diabetes Center at Park Nicollet

Completed

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

Hyperglycemia

United States
Wockhardt

Completed

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

Type1 Diabetes

United States
Sanofi

Completed

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (GAUDI)

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM) (LixilanOne CAN)

Type 2 Diabetes Mellitus

Canada
Medical University of Vienna

Completed

Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin (LixiBIT)

Type 2 Diabetes Mellitus

Austria
Sanofi

Completed

Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus

Type1 Diabetes

Germany
University of Padova

Completed

Endothelial Effects of Basal Insulin: Detemir Versus Glargine

Cardiovascular Disease | Type 2 Diabetes | Endothelial Dysfunction

Italy
Munich Municipal Hospital
Aventis Pharmaceuticals

Unknown

Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)

Coronary Artery Disease | Type 2 Diabetes

Germany
Novo Nordisk A/S

Completed

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Diabetes Mellitus, Type 2

United States, Poland, Slovakia, Canada, Slovenia, Greece, Czechia
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-L)

Type 2 Diabetes

United States, Australia, Canada, Chile, Czech Republic, Denmark, Estonia, Hungary, Lithuania, Mexico, Netherlands, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine
Federico II University

Completed

One Year Glargine Treatment in CFRD Children and Adolescents

Glucose Metabolism Disorders | Cystic Fibrosis

Italy
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR)

Completed

Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial) (RESET-IT)

Type 2 Diabetes

Canada
Baylor College of Medicine

Completed

The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients (GIH)

Hyperglycemia | Diabetes Mellitus

United States
Sanofi

Completed

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

Diabetes Mellitus

United States
Washington University School of Medicine

Completed

Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients

Hyperglycemia | Lymphoma | Diabetes Mellitus, Type 2

United States
Merck Sharp & Dohme LLC

Terminated

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

Diabetes Mellitus, Type 2
Gan and Lee Pharmaceuticals, USA

Completed

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research (GLITTER1)

Diabetes Mellitus, Type 1

Spain, United States, Germany, Czechia, Hungary, Poland
Emory University

Completed

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients (CABG-D/C)

Poor Glycemic Control

United States
Sanofi

Completed

Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

Type 1 Diabetes Mellitus

Germany
Halozyme Therapeutics

Completed

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Xijing Hospital

Completed

Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
University of Colorado, Denver
Sanofi

Completed

Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

Diabetes

United States
Joslin Diabetes Center
Sanofi

Completed

Simplified Insulin Protocol Using Lantus in Elderly (SIMPLE)

Diabetes

United States
Diabetes Care Center
Novo Nordisk A/S

Completed

A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus (DUALTM IX)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Spain, Switzerland, Argentina, Finland, Hungary, Russian Federation, Slovenia, Slovakia
Chattanooga-Hamilton County Hospital Authority

Terminated

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

Diabetes Mellitus, Type 1 | Diabetic Ketoacidosis

United States
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States
Sanofi

Completed

Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) (B to B)

Diabetes Mellitus, Type 2

Korea, Republic of
University of Sao Paulo General Hospital

Completed

Glargine Versus NPH in Patients With Chronic Kidney Disease

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Brazil
Sanofi

Completed

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM (LixiLan-O)

Type 2 Diabetes

Australia, Denmark, South Africa, Spain, Belgium, Russian Federation, Canada, Estonia, Hungary, Latvia, Mexico, United States, Chile, Czech Republic, France, Germany, Italy, Lithuania, Poland, Romania, Sweden, Ukraine, United Kingdom
Medical University of South Carolina

Completed

IV Insulin Protocol in Diabetes and Renal Transplantation

Hyperglycemia | Diabetes | Kidney Transplantation

United States
AstraZeneca
Eli Lilly and Company

Completed

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

Type 2 Diabetes Mellitus

Italy, Poland, Hungary, Mexico, Greece, Australia
Yale University

Completed

Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs (PK/PD)

Diabetes Mellitus, Type I
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Slovakia, Spain, France, Hungary, Mexico, Russian Federation, Turkey, Czechia, Greece, Argentina
Brigham and Women's Hospital
Sanofi

Terminated

The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
LMC Diabetes & Endocrinology Ltd.
Sanofi

Completed

Long Acting Insulin Glargine Titration Web Tool (LTHome) vs Enhanced Usual Therapy of Glargine Titration (INNOVATE)

Type 2 Diabetes Mellitus

Canada
Population Health Research Institute

Completed

REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study) (RECREATE Pilot)

Hyperglycemia | Myocardial Infarction | Cardiovascular Diseases

Argentina, Canada, India

3

Subscribe